Last reviewed · How we verify
Herceptin (trastuzuamb)
Herceptin (trastuzuamb) is a HER2-targeted monoclonal antibody Small molecule drug developed by Samsung Bioepis Co., Ltd.. It is currently in Phase 3 development for HER2-positive metastatic breast cancer, HER2-positive early-stage breast cancer (adjuvant and neoadjuvant settings), HER2-positive metastatic gastric cancer. Also known as: Herceptin.
Trastuzumab is a monoclonal antibody that binds to HER2 receptors on cancer cells, blocking growth signals and triggering immune-mediated cell death.
Trastuzumab is a monoclonal antibody that binds to HER2 receptors on cancer cells, blocking growth signals and triggering immune-mediated cell death. Used for HER2-positive metastatic breast cancer, HER2-positive early-stage breast cancer (adjuvant and neoadjuvant settings), HER2-positive metastatic gastric cancer.
At a glance
| Generic name | Herceptin (trastuzuamb) |
|---|---|
| Also known as | Herceptin |
| Sponsor | Samsung Bioepis Co., Ltd. |
| Drug class | HER2-targeted monoclonal antibody |
| Target | HER2 (human epidermal growth factor receptor 2) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Trastuzumab targets human epidermal growth factor receptor 2 (HER2), a protein overexpressed in certain cancers. By binding to HER2, it prevents ligand-induced signaling and recruits immune cells to destroy HER2-positive cancer cells through antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC).
Approved indications
- HER2-positive metastatic breast cancer
- HER2-positive early-stage breast cancer (adjuvant and neoadjuvant settings)
- HER2-positive metastatic gastric cancer
Common side effects
- Cardiotoxicity / left ventricular dysfunction
- Infusion reactions
- Nausea
- Diarrhea
- Fatigue
- Headache
- Vomiting
Key clinical trials
- A Phase III Trial of Pertuzumab Retreatment in Previously Pertuzumab Treated Her2-Positive Advanced Breast Cancer (PHASE3)
- BN-Brachyury, Entinostat, Adotrastuzumab Emtansine and M7824 in Advanced Stage Breast Cancer (BrEAsT) (PHASE1)
- A Study to Compare the Effect of SB3 and Herceptin® in Women With HER2 Positive Breast Cancer (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Herceptin (trastuzuamb) CI brief — competitive landscape report
- Herceptin (trastuzuamb) updates RSS · CI watch RSS
- Samsung Bioepis Co., Ltd. portfolio CI
Frequently asked questions about Herceptin (trastuzuamb)
What is Herceptin (trastuzuamb)?
How does Herceptin (trastuzuamb) work?
What is Herceptin (trastuzuamb) used for?
Who makes Herceptin (trastuzuamb)?
Is Herceptin (trastuzuamb) also known as anything else?
What drug class is Herceptin (trastuzuamb) in?
What development phase is Herceptin (trastuzuamb) in?
What are the side effects of Herceptin (trastuzuamb)?
What does Herceptin (trastuzuamb) target?
Related
- Drug class: All HER2-targeted monoclonal antibody drugs
- Target: All drugs targeting HER2 (human epidermal growth factor receptor 2)
- Manufacturer: Samsung Bioepis Co., Ltd. — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for HER2-positive metastatic breast cancer
- Indication: Drugs for HER2-positive early-stage breast cancer (adjuvant and neoadjuvant settings)
- Indication: Drugs for HER2-positive metastatic gastric cancer
- Also known as: Herceptin
- Compare: Herceptin (trastuzuamb) vs similar drugs
- Pricing: Herceptin (trastuzuamb) cost, discount & access